Phase I Clinical Trial of a Candidate HPV Vaccine

Summary

This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.

Timeline

Start

2023-08-01

Primary completion

2024-07-31

Completion

2024-10-31

Publications

• Han Z, Wang S, Mu T, Zhao P, Song L, Zhang Y, Zhao J, Yin W, Wu Y, Wang H, Gong B, Ji M, Roden RBS, Yang Y, Klein M, Wu K. Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model. Vaccines (Basel). 2024 Jun 20;12(6):689. doi: 10.3390/vaccines12060689.

Drugs

Indications